BMS CEO Giovanni Caforio (File photo/AP)
January 1, 2021 09:59 AM ESTUpdated 10:15 AM
Deals

A $6B CVR goes pfffft as the game clock runs out on a New Year's dead­line for Bris­tol My­er­s' liso-cel ap­pli­ca­tion

John Carroll

Editor & Founder

The last sec­onds of 2020 have ticked away, drain­ing the last of the sand in the hour glass along with any re­main­ing hopes in a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times